Monopar reports Q3 net loss $1.3M; in-licensed Wilson disease drug ALXN-1840; raised $17.7M

Monopar Therapeutics

Net loss Q3 2024 $1.3M ($0.37/share) vs $2.0M ($0.69/share) Q3 2023.
Exclusive license from Alexion for ALXN-1840 (Wilson disease, Phase 3 completed); planning FDA discussions.
MNPR-101-Lu Phase 1a therapy trial active and enrolling in Australia; MNPR-101-Zr imaging trial shows tumor uptake.
Completed public offering Oct 30, 2024: 1,181,540 shares at $16.25/sh, net $17.7M.
Cash $6.0M at Sept 30; pro forma runway into first half 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.